ArticleThe American journal of gastroenterology2017
Editorial: Best Practices in Surveillance of Barrett's Esophagus.
Article in The American journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Barrett's Esophagus: An Updated Review.Diagnostics (Basel, Switzerland) · 2023Review
- Barrett's esophagus: current standards in advanced imaging.Translational gastroenterology and hepatology · 2021Review
- Endoscopic Eradication Therapy for Barrett's Neoplasia: Where Do We Stand a Decade Later?Current gastroenterology reports · 2020Review
- Reduced Esophageal Contractility Is Associated with Dysplasia Progression in Barrett's Esophagus: A Multicenter Cohort Study.Digestive diseases and sciences · 2020Article
- Endoscopic eradication therapy for Barrett's oesophagus: state of the art.Current opinion in gastroenterology · 2020Review
- Biomarker identification and trans-regulatory network analyses in esophageal adenocarcinoma and Barrett's esophagus.World journal of gastroenterology · 2019Article
- A Survey of Expert Practice and Attitudes Regarding Advanced Imaging Modalities in Surveillance of Barrett's Esophagus.Digestive diseases and sciences · 2018Article
- Barrett's Esophagus.Missouri medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endoscopic surveillance in Barrett's esophagus (BE) has numerous limitations and thus provides several opportunities for improving the effectiveness of our current surveillance strategies. Several risk stratification and prediction tools have been investigated to identify patients at highest risk for progression to esophageal adenocarcinoma (EAC). Persistence of non-dysplastic BE (NDBE) has been proposed as an indicator of lower risk of progression to EAC. This editorial highlights the variable results and methodologies in studies evaluating persistence of NDBE as a risk stratification tool in the surveillance of BE patients and provides guidance for optimizing outcomes in BE patients enrolled in surveillance programs.
Indexed as
Identifiers
28725066What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.